Stock Market Reviews

HSIC (Henry Schein, Inc.) News

Get the latest news, insights, and market updates on HSIC (Henry Schein, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Henry Schein to Participate in Upcoming Investor Conferences in March
  MELVILLE, N.Y., March 03, 2026--Henry Schein, Inc., the world’s largest provider of health care solutions to office-based dental and medical practitioners, announced today that the Company will present at the following conferences in March:
  Mar 3, 2026 - $HSIC
• Sotera Health Up 30% This Past Year, so Why Did One Fund Sell $4 Million in Shares?
  Sotera Health delivers sterilization and laboratory solutions to healthcare, pharmaceutical, and food industry clients worldwide.
  Mar 2, 2026 - $HSIC
• BlackLine Stock Down Nearly 30% as One Fund Cuts Stake by $10 Million
  BlackLine delivers cloud-based automation tools for enterprise finance teams, serving a global client base with a subscription SaaS model.
  Mar 2, 2026 - $HSIC
• 3 Profitable Stocks We Approach with Caution
  Even if a company is profitable, it doesn’t always mean it’s a great investment. Some struggle to maintain growth, face looming threats, or fail to reinvest wisely, limiting their future potential.
  Feb 27, 2026 - $HSIC
• How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
  Henry Schein’s assessed fair value in the model has been nudged from US$78.14 to US$83.21, signaling a slightly higher valuation range under the latest assumptions. That shift lines up with recent Street research, where several firms have lifted their price targets into the US$87 to US$100 band as sentiment around dental demand and organic growth improves. Read on to see what is driving this evolving narrative and how you can track the key factors analysts are watching. Analyst Price Targets...
  Feb 26, 2026 - $HSIC
• Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
  Physician Interview Now AvailableKey Highlights Responder Analysis: 59.4% of patients achieved ≥30% reduction in abdominal pain; 68.1% achieved ≥30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now availab
  Feb 26, 2026 - $HSIC
• Henry Schein Q4 Earnings Call Highlights
  Henry Schein (NASDAQ:HSIC) reported fourth-quarter 2025 results on Feb. 24, 2026, highlighting what management described as its “highest sales growth in 15 quarters,” alongside progress on its 2025–2027 BOLD+1 strategic plan and an update to its leadership transition. Leadership transition and stra
  Feb 24, 2026 - $HSIC
• Henry Schein (HSIC) Q4 2025 Earnings Transcript
  Graham Stanley: Thank you, Operator, and thanks to each of you for joining us today to discuss Henry Schein, Inc.'s financial results for 2025. With me on today's call are Stanley Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, Inc.; Fred Lowry, Chief Executive Officer designate of Henry Schein, Inc.; and Ronald South, Senior Vice President and Chief Financial Officer.
  Feb 24, 2026 - $HSIC
• Stocks Rise Pre-Bell Following Selloff Amid Tariff, AI Worries
  US equity futures were pointing higher on Tuesday following a selloff driven by renewed tariff uncer
  Feb 24, 2026 - $HSIC
• HSIC Q4 Earnings & Revenues Beat Estimates, Margins Down
  Henry Schein tops Q4 estimates with 7.8% sales growth, but margin contraction tempers strong equipment, specialty and tech gains.
  Feb 24, 2026 - $HSIC